Micell's technology is designed to enable stable, controlled-release delivery of 'limus drugs (e.g. sirolimus, also known as rapamycin) and provides targeted pharmacokinetic profiles to optimize local dosing and healing.
Micell's platform technology enables a portfolio of proprietary and advanced devices for multiple indications. In summary, Micell's technology platform has been designed to make clinically meaningful improvements in patient outcomes:
|KEY FEATURE||TARGETED POTENTIAL CLINICAL BENEFIT|
|Composition controlled and completely absorbed for local therapy||
More consistent tissue response
No liability of long-term polymer exposure
|Linear pharmacokinetic profile of the drug concurrent with the absorption of a bioabsorbable polymer||Optimize healing and safety|
|Drug is maintained in a crystalline morphology; enabled by Micell's novel process and formulation technology||Ensure stability and sustained potency of the drug both on the shelf and in vivo|